Esomeprazole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Esomeprazole: From Gastroesophageal Reflux Disease to Duodenogastric Reflux
One-Sentence Summary
Esomeprazole is a proton pump inhibitor (PPI) widely used globally for gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori eradication — though it currently holds no regulatory registration in Singapore. The TxGNN model predicts it may be effective for Duodenogastric Reflux, with no registered clinical trials and 1 review publication currently supporting this specific direction. The mechanistic rationale is indirect, and evidence specific to this indication is insufficient for a clinical development decision at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gastroesophageal reflux disease / acid-related diseases (globally recognised; no Singapore registration on record) |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L4 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not included in this evidence pack. Based on established pharmacology, Esomeprazole is the S-isomer of omeprazole — the first single-optical-isomer proton pump inhibitor developed for clinical use. It irreversibly binds and inhibits the H⁺/K⁺-ATPase enzyme on gastric parietal cells, suppressing acid secretion and maintaining intragastric pH above 4 for 14–16 hours per dose. This makes it the most potent acid-suppressive agent in its class.
Duodenogastric reflux involves retrograde flow of duodenal contents (bile acids, pancreatic enzymes, and intestinal secretions) into the stomach. Although bile acids are the primary mucosal irritant in this condition, they are typically mixed with gastric acid, and the resulting acidic-bile mixture amplifies epithelial injury. By reducing the acidic component of the refluxate, Esomeprazole may partially attenuate mucosal damage — giving the TxGNN model a pharmacological basis to flag this association.
However, the mechanistic link is indirect and limited. Esomeprazole has no direct effect on bile acid reflux itself, nor on the pyloric dysfunction or motility abnormalities that drive duodenogastric reflux. The TxGNN high prediction score most likely reflects shared knowledge-graph nodes around "gastric mucosal protection" and "acid suppression" rather than a specific mechanistic connection to duodenogastric reflux as a distinct disease entity. Clinically, bile acid sequestrants or prokinetics — not PPIs — are considered more mechanistically aligned treatments for this condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18679668 | 2008 | Review | European Journal of Clinical Pharmacology | Broad PPI class update covering Esomeprazole clinical uses: peptic ulcer, H. pylori eradication, GERD, NSAID-induced GI lesions, and Zollinger-Ellison syndrome. Duodenogastric reflux is not addressed as a distinct indication. |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale for Esomeprazole in duodenogastric reflux is indirect — acid suppression may reduce mucosal injury from the acidic component of refluxate, but bile acids (the primary pathological driver) are entirely unaffected. With zero registered clinical trials and only a single general PPI review paper, there is no direct clinical evidence to support advancement.
To proceed, the following is needed:
- Dedicated clinical trials evaluating Esomeprazole specifically for duodenogastric reflux endpoints (e.g., endoscopic mucosal healing, validated symptom scales such as the Bile Reflux Symptom Score)
- Mechanistic studies clarifying whether acid suppression alone produces clinically meaningful mucosal protection in the context of bile acid-predominant reflux
- Singapore HSA regulatory pathway assessment, as Esomeprazole currently has no local registration
- Full package insert safety review (FDA/EMA labelling) to address current data gaps in warnings, contraindications, and drug-drug interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.